Disclosures: Max Schechter: Nothing to Disclose, Katherine Ni: Nothing to Disclose, Zoe Verzani: Nothing to Disclose, Kimberline Chew: Nothing to Disclose, Jang Hyun Kim: Nothing to Disclose, Lewis Paulino: Nothing to Disclose, Danielle Garfunkel: Nothing to Disclose, Lital Aliasi-Sinai: Nothing to Disclose, Daniel Alvarez: Nothing to Disclose, Adejoke Johnson: Nothing to Disclose, Soaptarshi Paul: Nothing to Disclose, Hamza Sadhra: Nothing to Disclose, Clara Tow: Nothing to Disclose, Don Rockey: WL Gore and Associates: Consultant, Cook Medical: Consultant, BD Medical: Consultant, AstraZeneca: Grant/Research Support, Direct: Grant/Research Support, Bio89: Grant/Research Support, Boehringer Ingelheim: Grant/Research Support, Durect: Grant/Research Support, Gilead: Grant/Research Support, Ipsen: Grant/Research Support, Intercept: Grant/Research Support, Inventiva: Grant/Research Support, Madrigal: Grant/Research Support, Ocelot: Grant/Research Support, Salix: Grant/Research Support, Novonordisk: Grant/Research Support, Galectin: Grant/Research Support, Versantis: Grant/Research Support, Viking: Grant/Research Support 1674 EARLY PALLIATIVE CARE (PC) IN END-STAGE LIVER DISEASE (ESLD) PATIENTS SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE (HRQOL) Shirley Bong 1 Calvin Koh 1 Jonathan Lee 1 Mark Muthiah 1 Guan Huei Lee 1 Lin Liu 2 Yin Mei Lee 1 , 1 National University Hospital, 2 National University Singapore Background: ESLD is characterized by recurrent complications and repeated visits to the emergency room (ER) and hospital admissions
Keep it toward the back
, , , ,
The 3-year OS rates for the four groups (high AFP & high PIVKA-II, high AFP & low PIVKA-II, low AFP & high PIVKA-II, low AFP & low PIVKA-II) were 31.7%, 67.3%, 51.6%, and 70.0%, respectively (p 25%) tumor shrinkage were 58.0% (57 participants at risk) versus 36.0% (8 participants at risk) at 48 months and 50.7% (34 participants at risk) versus 26.3% (4 participants at risk) at 60 months for STRIDE versus sorafenib, respectively
